Can You Market a Medical Device Before FDA Clearance?

The timing problem is real. You are eighteen months from launch. Your competitors are already talking. Your investors want to see market signals. And your regulatory counsel is telling you to watch what you say.

The good news is that the restriction is narrower than most device-company marketers believe. The FDA's concern is preventing patients and clinicians from relying on uncleared devices for treatment decisions. That concern does not reach corporate awareness campaigns, scientific publications, category education, or building a prospect database.

Here is where the regulation draws the line.

What the Regulation Actually Prohibits

The clearest statutory statement of pre-clearance promotion limits applies to devices in clinical investigations under an Investigational Device Exemption (IDE). 21 CFR 812.7 prohibits sponsors, investigators, and anyone acting on their behalf from:

• Promoting or test marketing an investigational device until after the FDA has approved the device for commercial distribution.
• Representing that the device is safe or effective for the purposes for which it is being investigated.
• Commercializing an investigational device by charging subjects or investigators more than cost recovery.

If your device is in a clinical trial under an IDE, these restrictions apply by regulation. You cannot run ads for the device, imply it works for its intended use, or accept payment as if it were a commercial product.

Outside of the IDE context, the legal framework for pre-clearance promotion is less codified in a single rule, but the underlying principle is consistent: promoting a device for its intended medical use, without the required FDA marketing authorization, can render the device misbranded (section 502 of the FD&C Act, 21 U.S.C. 352) or adulterated (section 501, 21 U.S.C. 351). Introducing such a device into interstate commerce is a prohibited act under 21 U.S.C. 331(a). The intended use of a device is established, in part, by how the manufacturer promotes it. Promote a device as a tool to diagnose or treat a condition before you have clearance for that use, and you have established an intended use that you cannot legally support.

The Permitted Side of the Line

The following activities do not constitute promotion of an uncleared device for its intended use, and the FDA's enforcement history does not target them.

Corporate and company-level awareness

Publishing content about your company, your founding story, your team, your funding rounds, or your scientific approach is not product promotion. Announcing that your company is developing a novel diagnostic platform, that you recently closed a Series B, or that your scientific advisory board includes prominent researchers is all permitted. None of this constitutes a claim that a specific uncleared product is safe, effective, or available for use.

Category education and thought leadership

Publishing articles, white papers, webinars, or conference presentations about the clinical problem your device will address is permitted. If your company is developing a wound-healing device, you can publish a detailed article about chronic wound management, the limitations of current standard of care, and the relevant clinical literature. You are educating the market. You are not promoting an uncleared device.

Scientific publication

Publishing peer-reviewed study results, presenting at scientific conferences, and making your clinical data available to the research community are activities the FDA explicitly supports as part of the development process. Accurate, non-promotional presentation of clinical data is different from commercial promotion.

Press about your company and pipeline

Press releases announcing funding, partnerships, FDA submissions, or the fact that you are developing a product in a given category are standard practice. The constraint is accuracy: if you have submitted a 510(k) and are awaiting a decision, you can say "we have submitted a 510(k) to the FDA." You cannot say "our device is cleared" or imply clearance is certain.

Audience capture and CRM building

Building an email list of interested clinicians, hospital procurement contacts, or patient advocacy groups is permitted. Inviting people to register for updates about your launch is permitted. Collecting interest and intent signals from your target market is not the same as taking orders.

The Prohibited Side of the Line

The following activities cross into pre-clearance promotion and create regulatory risk.

Promoting a specific device for its medical intended use

Telling clinicians or patients that your specific device treats, diagnoses, or monitors a condition, before it has been cleared or approved for that use, is the core violation. This includes product-specific web pages with intended-use claims, sales conversations in which the device's therapeutic function is promoted, and print or digital advertising that presents the device as a solution for a medical condition.

Taking orders or accepting payment

Accepting purchase orders, or deposits for uncleared devices, is commercialization. Distributing a device that requires clearance or approval before it has one can make the device misbranded or adulterated, and introducing it into interstate commerce is a prohibited act under 21 U.S.C. 331(a). In the IDE context, charging more than cost recovery is separately prohibited by 21 CFR 812.7. If you are selling a device that has not been cleared, you are operating outside the regulatory framework regardless of whether you call it a reservation, a pilot, or a development partnership. The line between a non-binding expression of interest and a commercial order can be fact-specific, so structure any pre-clearance commercial arrangement with your regulatory counsel.

"Coming soon" copy with claims

The phrase "coming soon" is not the issue. The issue is what surrounds it. "Coming soon: an FDA-cleared device for monitoring [condition]" is permissible if you have clearance. "Coming soon: the most accurate device for monitoring [condition], FDA clearance pending" combines a performance claim with an uncleared intended use. The performance claim establishes an intended use the device does not yet have authorization to support.

Implying clearance before it exists

Saying "we expect clearance in Q3" as part of a product description, or using language like "when cleared, this device will be indicated for" followed by a detailed marketing pitch, can establish the commercial context that makes the subsequent promotion a pre-clearance issue. Your regulatory counsel should review any forward-looking statements about clearance timelines in marketing copy.

The Distinction Between Unbranded (Corporate) and Branded (Product) Awareness

The clearest practical test is whether the content is about your company and the problem it is working on, or about a specific uncleared product and what that product will do for patients or clinicians.

What Pre-Submission Meetings and the "Pre-Sub" Program Mean for Your Marketing

The FDA offers Pre-Submission (Pre-Sub) meetings (formerly called Pre-IDE meetings) through which you can receive feedback on your proposed regulatory strategy before filing. These meetings are about regulatory planning, not marketing. Their existence does not create a marketing authorization. Attending a Pre-Sub and receiving FDA feedback does not permit you to claim FDA involvement with or endorsement of your device.

Some companies communicate about their Pre-Sub interactions in investor materials and press, which is acceptable if described accurately ("we have met with the FDA to discuss our regulatory pathway") and not used to imply endorsement or imminent clearance.

A Note on Digital Marketing and Search Visibility

Building a digital presence before clearance is both possible and advisable. SEO content about the clinical landscape, your company's approach, and the science behind your technology establishes domain authority and creates an audience before launch day. What that content cannot do is function as a product promotion for an uncleared device. A company blog that publishes clinically grounded articles about wound care, cardiac arrhythmia monitoring, or orthopedic repair is building search equity and audience. A company product page that describes an uncleared device's intended use is not.

A medtech marketing agency with a regulatory review step built into its content process can help your team build meaningful pre-launch authority without crossing into claims that require clearance to support. Buzzbox Media works exclusively with medical device and healthcare companies. Our content process includes review against cleared indications at every stage. If you are nine to eighteen months from launch and want to build the right foundation, a 30-minute call is the place to start. Learn more about our medical device marketing services or book at https://www.buzzboxmedia.com/book.

Related Reading in This Series

Once your device clears, the questions change. These companion articles cover what happens next:

• The Post-510(k) Launch Playbook: Your First 90 Days After Clearance
• FDA Cleared vs FDA Approved: What You Can Legally Say in Your Medical Device Marketing
• Medical Device Marketing Claims the FDA Allows (and the Ones That Trigger Warning Letters)
• De Novo and PMA Launch Marketing: What You Can and Cannot Say

Frequently Asked Questions

See the full FAQ below.

Sources Cited

• 21 CFR Part 812, Investigational Device Exemptions (IDE): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812
• 21 CFR 812.7, Prohibition of Promotion and Other Practices: https://www.law.cornell.edu/cfr/text/21/812.7
• FD&C Act, Section 502 (21 U.S.C. 352), Misbranded devices: https://uscode.house.gov/view.xhtml?req=(title:21+section:352+edition:prelim)
• FD&C Act, Section 301 (21 U.S.C. 331), Prohibited acts (introduction of misbranded/adulterated devices into interstate commerce): https://www.law.cornell.edu/uscode/text/21/331
• FD&C Act, Section 501 (21 U.S.C. 351), Adulterated devices: https://www.law.cornell.edu/uscode/text/21/351
• FDA, Investigational Device Exemption (IDE): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/investigational-device-exemption-ide
• FDA, How to Study and Market Your Device: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/how-study-and-market-your-device
• FDA, Premarket Notification 510(k): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
• FDA, Pre-Submission Program (Formerly Pre-IDE and Pre-PMA Programs): https://www.fda.gov/media/72765/download